Wall Street analyst estimates for Senseonics Holdings, Inc. (SENS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices.
Valuation Ratios
| Price / Book | 5.75 |
| EV / EBITDA | -3.69 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $332000 | $6.4M | $18.9M | $21.3M | $4.9M | $13.7M | $16.4M | $22.4M | $22.5M | $35.3M |
| Cost of Revenue | $660000 | $9.8M | $27.1M | $40.7M | $22.3M | $14.5M | $13.7M | $19.3M | $21.9M | $19.5M |
| Gross Profit | -$328000 | -$3.4M | -$8.1M | -$19.4M | -$17.4M | -$811000 | $2.7M | $3.1M | $533000 | $15.8M |
| Research & Development | $26.3M | $30.7M | $31.9M | $38.4M | $20.4M | $27.2M | $39.7M | $48.8M | $41.1M | $31.6M |
| Selling, General & Admin | $15.8M | $22.2M | $47.6M | $72.8M | $41.4M | $29.2M | $31.6M | $29.9M | $34.2M | $52.5M |
| Operating Expenses | $42.1M | $52.9M | $79.4M | $111.2M | $61.8M | $56.4M | $71.4M | $78.7M | $75.4M | $84.1M |
| Operating Income | -$42.4M | -$56.3M | -$87.6M | -$130.7M | -$79.1M | -$57.2M | -$68.6M | -$75.6M | -$74.8M | -$68.3M |
| EBITDA | -$42.2M | -$55.8M | -$85.4M | -$99.4M | -$157.9M | -$284.5M | $161.8M | -$48.0M | -$68.7M | -$62.6M |
| Interest Expense | $1.6M | $3.1M | $8.3M | $15.1M | $16.2M | $16.7M | $18.7M | $11.1M | $8.4M | $5.0M |
| Pre-tax Income | -$43.9M | -$59.1M | -$94.0M | -$115.5M | -$175.2M | -$302.5M | $142.1M | -$60.4M | -$78.6M | -$69.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$43.9M | -$59.1M | -$94.0M | -$115.5M | -$175.2M | -$302.5M | $142.1M | -$60.4M | -$78.6M | -$69.1M |
| EPS | $-9.80 | $-10.20 | $-12.00 | $-12.20 | $-15.40 | $-14.40 | $6.07 | $-2.20 | $-2.50 | $-1.66 |
| EPS (Diluted) | $-9.80 | $-10.20 | $-12.00 | $-12.20 | $-15.40 | $-14.40 | $-2.17 | $-2.20 | $-2.50 | $-1.66 |
| Shares Outstanding (Diluted) | $4.5M | $5.8M | $7.9M | $9.4M | $11.4M | $21.1M | $30.9M | $28.4M | $31.5M | $41.7M |
Price
| Price | $9.06 |
| Market Cap | $379M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACRS · CAPR · CERS · CVRX · MASS · NNOX · NPCE
Explore sector: Healthcare · Medical - Devices
More sections of SENS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks